Late Effects of Radiation Therapy and Natural History of Disease in Patients Previously Treated for Cancer at the National Institutes of Health
Summary
RATIONALE: Radiation therapy may cause side effects that appear months or years after treatment has ended. A study that evaluates patients for several years after they have undergone radiation therapy may help doctors provide the best follow-up care.
PURPOSE: This clinical trial is studying the late effects of radiation therapy and the natural history of disease over time in patients previously treated for cancer at the National Institutes of Health (NIH).
Description
OBJECTIVES:
- Continue follow-up care for long-term survivors and other patients who received radiotherapy at the National Cancer Institute's (NCI) Radiation Oncology Branch at the National Institutes of Health (NIH) in the past and for whom continued follow-up at NIH is considered beneficial to both the patient and the Radiation Oncology Branch.
- Assess the natural history of the disease in these patients.
- Assess late effects of treatment in these patients.
OUTLINE: Patients are evaluated by Radiation Oncology Branch staff at appropriate intervals (based on good medical practices) to determine the natural history of the disease, long-term effects of previous therapies, and potential eligibility for enrollment on future protocols. Diagnostic tests, evaluations, and subsequent treatments (if needed) vary according to the individual patient's circumstances. Data is collected to assist researchers in studying long-term effects of radiotherapy and outcomes of the disease.
PROJECTED ACCRUAL: A maximum of 300 patients will be accrued for this study.
Study Design
N/A
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Intervention
physiologic testing
Location
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda
Maryland
United States
20892
Status
Recruiting
Source
National Cancer Institute (NCI)
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00436813
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Mandatory Testing
Testing or screening required by federal, state, or local law or other agencies for the diagnosis of specified conditions. It is usually limited to specific populations such as categories of health care providers, members of the military, and prisoners or to specific situations such as premarital examinations or donor screening.
Nephroma, Mesoblastic
A solid, unencapsulated tumor of the KIDNEY composed of spindle mesenchymal cells that resemble FIBROBLASTS or muscle cells. The homogeneous mass typically extends into the renal parenchyma and replaces most of the kidney. In most cases, mesoblastic nephroma is benign and occurs in the fetus or newborn, and rarely in the older child or the adult.
Tumor Stem Cell Assay
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
Genetic Testing
Detection of or testing for certain ALLELES, mutations, genotypes, or karyotypes that are associated with genetic traits, heritable diseases, or with a predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing.
Clinical Trials
Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Measuring how well the lungs work in patients with cancer may help doctors predict how patients will respond to treatment and help plan the best treatment. PURPOSE: This clinic...
GPX-100 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in tre...
S-3304 in Treating Patients With Advanced Solid Tumors
RATIONALE: S-3304 may stop or slow the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of S-3304 in treating patients who hav...
EMD 121974 in Treating Patients With Advanced Solid Tumors
RATIONALE: EMD 121974 may slow the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who...
SJG-136 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as SJG-136, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: T...
PubMed Articles
Introduction: The enhancement in pediatric cancer survival achieved in the past few decades has been confined to low- and moderate-risk cancers, whereas no notable improvement in survival was observed...
Adult type 2 diabetes patients with GAD65 autoantibodies (GADA) are known as latent autoimmune diabetes in adults (LADA). It has been suggested that GADA in LADA patients preferentially bind to the N-...
FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines.
A single, recurrent somatic point mutation (402CG) in FOXL2 has been described in almost all adult-type granulosa cell tumors but not other ovarian neoplasms. Histopathological features of adult-ty...
In this short communication we describe a specific protocol for SDS-PAGE separation of adult bovine myosin heavy-chain (MyHC) isoforms. The conditions defined in this protocol allow a good separation...
Short-term adult fish reproductive tests are widely used to assess the toxicity of chemicals and waste streams. However, these tests often have low power to detect differences in egg production among...
